Quality of life , as indicated by SNOT-22 , did not differ between groups at 60 days ( p = 0.404 ; 95 % confidence interval [ CI ] , -37.2 to 15.9 ) , but SNOT-22 scores for patients using MAD did show statistically significant improvement at 60 days compared to baseline ( p = 0.02 ) .